Newsletters

PBI is active in the community, providing educational information to patients and their families on living with a blood disorder. Additionally, we regularly hold events for both health professionals and members of the community.

We are pleased to outline exciting developments at PBI through regular and diverse communications with our stakeholders.

Read our latest email newsletter

Archived issues of Blood Matters newsletters are available to download:

We now send news and event updates by email. Read our latest email newsletter here or subscribe to future editions below.

Latest

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab (Cancer - Recruitment: OPEN)

A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors.
Create your #Thirty4Thrombosis fundraising page!

Information on how to set up a fundraising page for the Thirty4Thrombosis appeal.
Thirty4Thrombosis Appeal

Thrombosis is a potentially serious condition that involves a blood clot forming in a blood vessel, usually in the deep veins of the leg. Sitting for many hours can double your risk of thrombosis. Join our 30-day exercise challenge and get your body moving while you are working! Funds raised will help PBI to promote the importance of exercise to minimise the risk of developing deep vein thrombosis!
COVID-19 and Thrombosis: Information for Professionals

The landscape of managing patients with COVID-19 continues to change. New research suggests acute medical illness, such as COVID-19, and hospitalisation confer a greater risk of venous thromboembolism (VTE). Also, Coagulopathy in COVID-19 patients appears to be associated with poor prognosis, an effect common in patients with sepsis.

Accessibility
Make a bequest
Perth Blood Institute

Your donation can help PBI to fund vital translational research into blood disorders including thrombosis and haemophilia; support a clinical research investigation into the development of a new treatment or intervention; or help us develop educational programs to foster the next generation of career haematologists.
Multiple Myeloma Clinical Trials Appeal

PBI is committed to developing new treatments for blood cancers and facilitates patient participation in clinical trials to access potentially lifesaving treatments not currently available elsewhere. Your support will enable us to participate in testing new treatment options to improve the health outcomes for patients with blood disorders, including multiple myeloma.
Research Team Awarded DARF Dementia Grant

Perth Blood Institute is pleased to announce it is the recipient of the Norma Beaconsfield Project Grant, awarded by the Dementia Australia Research Foundation (DARF). This grant will allow the Platelet Research Team to continue important investigations into the effect of blood-thinning medication on dementia risk.
Privacy Policy

THE PERTH BLOOD INSTITUTE LIMITED ABN: 24164941815 (trading as Perth Blood Institute) takes your privacy seriously. We respect and uphold your right to privacy protection under the Australian Privacy Principles (APPs), by regulating the way in which we collect, use, disclose, hold and destroy your personal information. This Privacy Policy covers all personal information held by us.
What are DVT & PE?

Click here to learn more about DVT and PE.
COVID-19 - Impact on blood transfusions and blood donations

Some members of the community may be concerned about the potential transmission of the COVID-19 virus through blood products, such as through blood transfusions. If you rely on blood products, you should feel confident to continue to receive them.
COVID-19 and Thrombosis

Click here for frequently asked questions and links to resources regarding COVID-19 and thrombosis.
Terms and Conditions

Perth Blood Institute

Your donation can help PBI to fund vital translational research into blood disorders including thrombosis and haemophilia; support a clinical research investigation into the development of a new treatment or intervention; or help us develop educational programs to foster the next generation of career haematologists. Read more

Donate Fundraise